NCT06533813 Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
| NCT ID | NCT06533813 |
| Status | Recruiting |
| Phase | — |
| Sponsor | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS |
| Condition | Myelofibrosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 617 participants |
| Start Date | 2024-10-14 |
| Primary Completion | 2025-12-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 617 participants in total. It began in 2024-10-14 with a primary completion date of 2025-12-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of primary myelofibrosis (PMF) or secondary (i.e., post-ET/PV MF) myelofibrosis according to 2016- or 2022-WHO criteria ascertained between 01/01/2018 and 31/12/2027 * Age ≥ 18 years * Signed informed consent where applicable, in line with current European General Data Protection Regulation (GDPR) directives Exclusion Criteria: * Diagnosis of early/prefibrotic primary myelofibrosis * Concurrent participation to interventional clinical trials in MF
Contact & Investigator
TIZIANO BARBUI, MD
STUDY DIRECTOR
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Frequently Asked Questions
Who can join the NCT06533813 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Myelofibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06533813 currently recruiting?
Yes, NCT06533813 is actively recruiting participants. Contact the research team at tbarbui@fondazionefrom.it for enrollment information.
Where is the NCT06533813 trial being conducted?
This trial is being conducted at Yerevan, Armenia, Copenhagen, Denmark, Paris, France, Greifswald, Germany and 11 additional locations.
Who is sponsoring the NCT06533813 clinical trial?
NCT06533813 is sponsored by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS. The principal investigator is TIZIANO BARBUI, MD at FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS. The trial plans to enroll 617 participants.